



CORRECTION

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine

Yehuda Handelsman · Marcel H. A. Muskiet · Graydon S. Meneilly

Published online: December 23, 2019
© The Author(s) 2019

Correction to: Adv Ther (2019) 36:3321–3339
<https://doi.org/10.1007/s12325-019-01126-x>

On page 3331 of the original article, the word, “/LYXUMIA” has been removed from the section RATIONALE FOR COMBINATION THERAPY COMPRISING GLP-1 RAs AND BASAL INSULIN and the associated reference, numbered 100, has been corrected to: Xultophy® (insulin degludec/liraglutide) [summary of product characteristics]. Bagsvaerd, Denmark: Novo Nordisk A/S https://www.ema.europa.eu/en/documents/product-information/xultophy-par-product-information_en.pdf. Accessed November 2019.

The original article can be found online at <https://doi.org/10.1007/s12325-019-01126-x>.

Y. Handelsman (✉)
Metabolic Institute of America, 18372 Clark St. Suite 212, Tarzana, CA 91356, USA
e-mail: yhandelsman@gmail.com

M. H. A. Muskiet
Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers (Location VUMC), 1081 HV Amsterdam, The Netherlands

G. S. Meneilly
Department of Medicine, The University of British Columbia, 2775 Laurel Street, Vancouver, BC V5Z1M9, Canada

OPEN ACCESS

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.